AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
77.56
-0.49 (-0.63%)
At close: Sep 16, 2025, 4:00 PM EDT
77.56
0.00 (0.00%)
After-hours: Sep 16, 2025, 4:05 PM EDT
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$608,192
Profits / Employee
$89,290
Market Cap
240.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AZN News
- 1 day ago - AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Benzinga
- 1 day ago - AstraZeneca shares down 3% after rating cut, UK investment pause - Reuters
- 1 day ago - AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site - WSJ
- 4 days ago - AstraZeneca pauses £200mn Cambridge investment amid UK pharma uncertainty - Invezz
- 4 days ago - Exclusive: AstraZeneca pauses $270 million investment in Britain - Reuters
- 6 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 13 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 14 days ago - AstraZeneca: Buy This Pharma Star Now For Upside Potential - Seeking Alpha